LINDSTROM RICHARD L MD 4

What Happened

• Richard L. Lindstrom, M.D., a director of Ocular Therapeutix, was granted awards on June 10, 2026: 14,000 shares (acquired) and 44,000 derivative shares (RSUs). Both were reported at $0.00 per share (no cash paid), for a combined 58,000 shares/RSU-equivalents.
• These were award/grant transactions (code A). The awards are subject to vesting tied to continued board service and are not open-market purchases or sales.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (appears timely under the 2‑business‑day rule).
• Prices reported: $0.00 per share for both items; total reported value $0.
• Shares acquired: 14,000 (direct) + 44,000 (derivative/RSU) = 58,000 underlying shares.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnotes:
  • F1: Confirms the grant consists of restricted stock units (RSUs); each RSU equals one share and will vest subject to continued board service.
  • F2: Describes the vesting schedule — 100% of the awards vest on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders.
• Transaction code: A = Award/Grant; derivative designation indicates RSUs (right to receive shares upon vesting).

Context

• These awards are standard director compensation and vest based on continued service; they do not reflect an open‑market purchase or sale. Because they were granted (not bought or sold) and vest over time, they are more of a compensation event than an immediate market sentiment signal.